Turn Therapeutics Inc. (TTRX)
TTRX moved a median of -0.45% 30 minutes after news, and -1.40% by the close. How TTRX actually reacts to news — the realized, point-in-time move the market made, measured across 92 labeled events over the last three years with zero look-ahead.
TTRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 88 |
| 30-min | -0.45% | 32% | 92 |
| 60-min | +0.39% | 53% | 92 |
| to close | -1.40% | 35% | 89 |
| Middle 50% of TTRX reactions | -1.39% to +1.28% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 92 |
Half of all Turn Therapeutics Inc. news events land between -1.39% and +1.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TTRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TTRX's baseline. Nothing else.
Recent TTRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form ARS Turn Therapeutics Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -0.66% | |
| Form DEF 14A Turn Therapeutics Inc. For: Nov 30 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.66% | |
| Form 8-K Turn Therapeutics Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +4.49% | |
| Form 8-K Turn Therapeutics Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +3.52% | +0.30% | |
| Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum | Press release | Business Wire | +3.52% | +0.30% | |
| Form 8-K Turn Therapeutics Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +9.04% | |
| Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer | Press release | Business Wire | +1.51% | +9.04% | |
| Form D Turn Therapeutics Inc. | SEC filing · Form D | SEC EDGAR | +0.00% | +5.97% | |
| Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch | Press release | Business Wire | — | -2.85% | |
| Form 8-K Turn Therapeutics Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.46% | |
| Form 8-K Turn Therapeutics Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.46% | |
| Form 10-Q Turn Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -4.46% | |
| Form 8-K Turn Therapeutics Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.46% | |
| Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results | Press release | Business Wire | +0.00% | -4.46% | |
| Form 8-K Turn Therapeutics Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.41% | |
| Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 | Press release | Business Wire | +0.00% | -1.41% | |
| Form 8-K Turn Therapeutics Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | +22.29% | |
| Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis | Press release | Business Wire | -1.64% | +22.29% | |
| Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis | Press release | Business Wire | -1.64% | +22.29% | |
| Form 8-K Turn Therapeutics Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | -4.44% | |
| Form 8-K Turn Therapeutics Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +13.04% | |
| Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis | Press release | Business Wire | +1.04% | +13.04% | |
| Form 8-K Turn Therapeutics Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | -3.29% | |
| Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model | Press release | Business Wire | +0.18% | -3.29% | |
| Form 8-K Turn Therapeutics Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -6.76% | |
| Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 | Press release | Business Wire | -1.91% | -6.76% | |
| Form 8-K Turn Therapeutics Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | +17.79% | |
| Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead | Press release | Business Wire | +3.08% | +17.79% | |
| Form C-TR Turn Therapeutics Inc. | SEC filing · Form C-TR | SEC EDGAR | — | +3.08% | |
| Form 10-Q Turn Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.46% | |
| Form 8-K Turn Therapeutics Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.46% | |
| Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | Business Wire | +0.00% | +4.46% | |
| Form EFFECT Turn Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +6.40% | -0.89% | |
| Form 10-K Turn Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.52% | +2.13% | |
| Form 8-K Turn Therapeutics Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +4.52% | +2.13% | |
| Form POS AM Turn Therapeutics Inc. | SEC filing · Form POS | SEC EDGAR | +4.52% | +2.13% | |
| Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates | Press release | Business Wire | +4.52% | +2.13% | |
| Form 8-K Turn Therapeutics Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.62% | |
| Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group | Press release | Business Wire | +0.00% | -2.62% | |
| Form 8-K Turn Therapeutics Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | — | -9.61% | |
| Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs | Press release | Business Wire | — | -9.61% | |
| Form 8-K Turn Therapeutics Inc. For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.26% | |
| Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences | Press release | Business Wire | +0.00% | -4.26% | |
| Form 8-K Turn Therapeutics Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.64% | |
| Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.00% | -7.64% | |
| Form 8-K Turn Therapeutics Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.09% | |
| Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors | Press release | GlobeNewswire | +0.00% | +1.09% | |
| Form 10-Q Turn Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.18% | — | |
| Form 8-K Turn Therapeutics Inc. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | — | |
| Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -1.18% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TTRX section they belong to.
Where else TTRX is measured.
TTRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Turn Therapeutics Inc.'s median reaction calculated?
Every labeled TTRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 92 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 32% of TTRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TTRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.